Genetic engineering of T-cell receptors: TCR takes to titin

Heslop, Helen E.

doi:10.1182/blood-2013-06-509604

Cited by 3 publications

(1 citation statement)

References 8 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Encouraging results were shown in a study in which a TCR from a patient who had a sustained and robust CTL response against the HIV-1 p17 Gag-derived antigen SL9 was cloned and expressed in primary CD8 + cells 162 , and a Phase 1 clinical trial is being carried out (clinicaltrials.gov identifier NCT00991224 ). Nonetheless, this novel and promising tool should be carefully explored owing to potential off-target toxicities 163 . Although such approaches might be too resource-intensive to be implemented on a global scale, they may provide proof-of-concept that could lead to strategies that are appropriate for global implementation.…”

Section: Clearing Persistently Infected Cellsmentioning

confidence: 99%

Eradicating HIV-1 infection: seeking to clear a persistent pathogen

et al. 2014

View full text Add to dashboard Cite

Effective antiretroviral therapy (ART) blunts viraemia, which enables HIV-1-infected individuals to control infection and live long, productive lives. However, HIV-1 infection remains incurable owing to the persistence of a viral reservoir that harbours integrated provirus within host cellular DNA. This latent infection is unaffected by ART and hidden from the immune system. Recent studies have focused on the development of therapies to disrupt latency. These efforts unmasked residual viral genomes and highlighted the need to enable the clearance of latently infected cells, perhaps via old and new strategies that improve the HIV-1-specific immune response. In this Review, we explore new approaches to eradicate established HIV-1 infection and avoid the burden of lifelong ART.

show abstract

Section: Clearing Persistently Infected Cellsmentioning

confidence: 99%